Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Goodwill (2017 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Goodwill for 9 consecutive years, with $44.0 million as the latest value for Q4 2025.

  • Quarterly Goodwill changed 0.0% to $44.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.0 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $44.0 million for FY2025, 0.0% changed from the prior year.
  • Goodwill for Q4 2025 was $44.0 million at Ultragenyx Pharmaceutical, down from $44.4 million in the prior quarter.
  • The five-year high for Goodwill was $44.4 million in Q1 2021, with the low at $44.0 million in Q4 2024.
  • Average Goodwill over 5 years is $44.4 million, with a median of $44.4 million recorded in 2021.
  • The sharpest move saw Goodwill changed 0.0% in 2021, then fell 0.91% in 2024.
  • Over 5 years, Goodwill stood at $44.4 million in 2021, then changed by 0.0% to $44.4 million in 2022, then changed by 0.0% to $44.4 million in 2023, then dropped by 0.91% to $44.0 million in 2024, then changed by 0.0% to $44.0 million in 2025.
  • According to Business Quant data, Goodwill over the past three periods came in at $44.0 million, $44.4 million, and $44.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.